U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Pharmaceutical Investing
Eisai and Merck Announce European Commission Grants Marketing Authorization for LENVIMA (lenvatinib) as First-Line Treatment in Adults with Advanced or Unresectable Hepatocellular Carcinoma Pharmaceutical Investing
GBT Expands Sickle Cell Disease Pipeline with Worldwide Licensing Agreement for Inclacumab for the Treatment of Vaso-occlusive Crisis Biotech Investing
Minerva Neurosciences Announces Findings Showing Effect of Roluperidone on Brain-Derived Neurotrophic Factor Biotech Investing
Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with Pint Pharma Pharmaceutical Investing
Rexahn Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate RX-5902 (Supinoxin) in combination with KEYTRUDA (pembrolizumab) for Triple Negative Breast Cancer Pharmaceutical Investing
Approval of Linzess Tablets 0.25 mg in Japan for Additional Indication of Chronic Constipation Pharmaceutical Investing
Can-Fite Announces Enrollment of First Patient in its Comfort Phase III Trial of Piclidenoson in Psoriasis Biotech Investing
Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias Pharmaceutical Investing
